Oncology – Gynecologic
RCT: Lenvatinib plus pembrolizumab improve outcomes compared to chemotherapy in patients with advanced endometrial cancer.
21 Jan, 2022 | 09:46h | UTCLenvatinib plus Pembrolizumab for Advanced Endometrial Cancer – New England Journal of Medicine
Commentary on Twitter
In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months and 11.4 months, respectively. https://t.co/lzqFDnhAQn pic.twitter.com/Tm2BJZuh1D
— NEJM (@NEJM) January 19, 2022
O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee.
20 Jan, 2022 | 08:59h | UTC
RCT: Paclitaxel and Carboplatin noninferior to Paclitaxel and Ifosfamide in patients with carcinosarcoma of the uterus or ovary.
18 Jan, 2022 | 09:10h | UTCRandomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Review: Endometrial cancer.
13 Dec, 2021 | 08:43h | UTCEndometrial cancer – Nature Reviews Disease Primers (free for a limited period – if the link is paywalled, try this one)
Infographic: Endometrial cancer (free for a limited period – if the link is paywalled, try this one)
RCT: Cytoreductive surgery for relapsed ovarian cancer.
2 Dec, 2021 | 09:51h | UTC
Recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic.
19 Nov, 2021 | 10:33h | UTC
A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.
4 Nov, 2021 | 09:58h | UTCRelated:
CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination
Meta-Analysis: Population-level Impact of HPV Vaccination Programs
Commentary on Twitter
NEW—Cervical cancer rates 87% lower in women offered vaccination against human papillomavirus (#HPV) between ages 12-13 than in previous generations, English study confirms.
First direct evidence of cervical cancer prevention using bivalent vaccine: https://t.co/HdQbGIKxZp pic.twitter.com/PMFermHGOv
— The Lancet (@TheLancet) November 3, 2021
RCT: Pembrolizumab for persistent, recurrent, or metastatic cervical cancer.
26 Sep, 2021 | 21:43h | UTCCommentary: KEYNOTE-826: Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer – The ASCO Post
Guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery.
26 Aug, 2021 | 08:32h | UTC
Cohort study: Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers.
20 Aug, 2021 | 08:39h | UTC
Commentary on Twitter
For #BRCA1 mutation carriers, longer duration of oral contraceptive use (>10 yr) is associated with a greater reduction in #OvarianCancer risk, and the protection is long term. https://t.co/HrrutgaYKX
— Anna Chichura, MD (@AnnaChichuraMD) July 3, 2021
ASCO Resource-Stratified Guideline: Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer.
8 Aug, 2021 | 23:38h | UTCCommentary: ASCO Publishes Resource-Stratified Guideline on Assessment and Treatment of Ovarian Cancer – The ASCO Post
Review: Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer
7 May, 2021 | 08:23h | UTCHyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review – JAMA Oncology (free for a limited period)
RCT: No benefit from immune checkpoint inhibitors in newly diagnosed stage III or IV ovarian cancer
25 Apr, 2021 | 20:57h | UTC
RCT: Treatments for vulnerable older adult women with ovarian cancer compared
23 Apr, 2021 | 08:15h | UTCEfficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: Vulnerable Older Adults With Ovarian Cancer—Time to Stop Undertreating (free for a limited period)
RCT: Secondary cytoreduction followed by chemotherapy vs. chemotherapy alone in platinum-sensitive relapsed ovarian cancer
10 Mar, 2021 | 08:18h | UTCSecondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
NEW online: SOC-1 trial—Secondary #cytoreduction followed by #chemotherapy versus chemotherapy alone in platinum-sensitive relapsed #ovariancancer #surgery #gyncsm https://t.co/cFq41Ck9EW pic.twitter.com/5gFsIGLBDA
— The Lancet Oncology (@TheLancetOncol) March 9, 2021
[Abstract Only] Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer
1 Oct, 2020 | 08:56h | UTCHPV Vaccination and the Risk of Invasive Cervical Cancer – New England Journal of Medicine
News Release: HPV vaccine effective against cervical cancer – Karolinska Institutet